DNPEP

Aspartyl aminopeptidase · Q9ULA0 · DNPEP on Sugi Atlas →

6,626 patent compounds predicted against DNPEP, 3,727 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1277891	0.68	4/20
SCHEMBL1277892	0.68	4/20
Hydrochloric Acid (SCHEMBL1277930)	0.66	4/20
SCHEMBL1619488	0.59	3/20
SCHEMBL11129	0.55	3/20
SCHEMBL4324004	0.55	3/20
Phenylalanine (SCHEMBL2215770)	0.55	3/20
Dl-Phenylalanine (SCHEMBL1253618)	0.54	3/20
Phenylalanine (SCHEMBL1253619)	0.54	3/20
SCHEMBL2215767	0.53	3/20
SCHEMBL1768387	0.53	3/20
SCHEMBL1769031	0.53	3/20
SCHEMBL1769033	0.53	3/20
SCHEMBL1769602	0.53	3/20
SCHEMBL3235398	0.52	3/20
SCHEMBL3614651	0.51	3/20
Hydrochloric Acid (SCHEMBL4023667)	0.51	3/20
Phenylalanine (SCHEMBL2214641)	0.50	3/20
SCHEMBL2911383	0.46	3/20
SCHEMBL1965523	0.40	3/20

Clinical trials — most relevant to DNPEP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock	PHASE4	COMPLETED
AN-PEP on Gluten Exposure in Celiacs	PHASE4	COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes	PHASE3	COMPLETED
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load	PHASE2/PHASE3	COMPLETED
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension	PHASE3	COMPLETED
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19	PHASE2/PHASE3	UNKNOWN
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Roflumilast in Non-CF Bronchiectasis Study (2019)	PHASE2	COMPLETED
Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma	PHASE2	COMPLETED
DEFINE - Evaluating Therapies for COVID-19	PHASE1/PHASE2	COMPLETED
A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction	PHASE1	COMPLETED
CoVID-19 Plasma in Treatment of COVID-19 Patients	EARLY_PHASE1	COMPLETED
Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms	EARLY_PHASE1	COMPLETED
Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms	EARLY_PHASE1	UNKNOWN
Ovarian Reserve and Matrix Metalloproteinases	nan	COMPLETED
DPP4 Activity, Microvascular Reactivity and Inflammation	nan	COMPLETED
Protein Digestion and Amino Acid Absorption in the Aging Gastrointestinal Tract	nan	COMPLETED
Neutral Endopeptidase for Early Detection of Acute Kidney Injury After Cardiac Surgery	nan	COMPLETED
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.	nan	COMPLETED
Clearance of Vasoactive Metabolites With Blood Purification	nan	RECRUITING
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method）	nan	COMPLETED
Effect of AN-PEP Enzyme on Gluten Digestion	nan	COMPLETED
Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients	nan	COMPLETED
APAP Hepatotoxicity After Therapeutic Doses	nan	UNKNOWN
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).	nan	COMPLETED
Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients	nan	COMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a DNPEP binder may also engage these)

Protein	Name	Similarity
Q5RBT2	—	1.000	Q5RBT2 →
Q9Z2W0	—	1.000	Q9Z2W0 →
Q2HJH1	—	0.997	Q2HJH1 →
Q9ULD0	—	0.988	Q9ULD0 →
Q9VUL1	—	0.988	Q9VUL1 →
Q7ZXP9	—	0.988	Q7ZXP9 →
Q87YC5	—	0.987	Q87YC5 →
C1DQM8	—	0.987	C1DQM8 →
Q19087	—	0.987	Q19087 →
D3ZQD3	—	0.987	D3ZQD3 →
A6V2H4	—	0.986	A6V2H4 →
Q5XHA8	—	0.986	Q5XHA8 →
Q4R4P6	—	0.986	Q4R4P6 →
B9RAJ0	—	0.986	B9RAJ0 →
Q4ZW15	—	0.986	Q4ZW15 →
Q68EW0	—	0.986	Q68EW0 →
B0KTU0	—	0.986	B0KTU0 →
A4VJG1	—	0.985	A4VJG1 →
Q6P286	—	0.985	Q6P286 →
Q2UPZ7	—	0.985	Q2UPZ7 →
O36014	—	0.985	O36014 →
A2ATU0	—	0.984	A2ATU0 →
Q88M44	—	0.984	Q88M44 →
Q3KFM3	—	0.984	Q3KFM3 →
Q923Z3	—	0.984	Q923Z3 →
Q5F3Z1	—	0.984	Q5F3Z1 →
Q2QMG2	—	0.983	Q2QMG2 →
Q8S6N5	—	0.983	Q8S6N5 →
Q42523	—	0.983	Q42523 →
Q48L80	—	0.983	Q48L80 →